Topical BioPharm Discovery Research and Development Unit

King of Prussia, PA, United States

Topical BioPharm Discovery Research and Development Unit

King of Prussia, PA, United States
SEARCH FILTERS
Time filter
Source Type

Catchpole I.,Topical BioPharm Discovery Research and Development Unit | Germaschewski V.,Topical BioPharm Discovery Research and Development Unit | Germaschewski V.,Kymab Ltd | Hoh Kam J.,University College London | And 10 more authors.
PLoS ONE | Year: 2013

Age-related macular degeneration (AMD) is a leading cause of legal blindness in the Western world. There are effective treatments for the vascular complications of neo-vascular AMD, but no effective therapies are available for the dry/atrophic form of the disease. A previously described transgenic CFH-gene deficient mouse model, (cfh-/-), shows hallmarks of early AMD. The ocular phenotype has been further analysed to demonstrate amyloid beta (Aβ) rich basement membrane deposits associated with activated complement C3. Cfh-/- mice were treated systemically in both prophylactic and therapeutic regimes with an anti-Aβ monoclonal antibody (mAb), 6F6, to determine the effect on the cfh-/- retinal phenotype. Prophylactic treatment with 6F6 demonstrated a dose dependent reduction in the accumulation of both Aβ and activated C3 deposition. A similar reduction in the retinal endpoints could be seen after therapeutic treatment. Serum Aβ levels after systemic administration of 6F6 show accumulation of Aβ in the periphery suggestive of a peripheral sink mechanism. In summary, anti-Aβ mAb treatment can partially prevent or reverse ocular phenotypes of the cfh-/- mouse. The data support this therapeutic approach in humans potentially modulating two key elements in the pathogenesis of AMD - Aβ and activated, complement C3. © 2013 Catchpole et al.

Loading Topical BioPharm Discovery Research and Development Unit collaborators
Loading Topical BioPharm Discovery Research and Development Unit collaborators